Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Scherzer, TM; Hofer, H; Staettermayer, AF; Rutter, K; Beinhardt, S; Steindl-Munda, P; Kerschner, H; Kessler, HH; Ferenci, P.
Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.
J HEPATOL. 2011; 54(5): 866-871.
Doi: 10.1016/j.jhep.2010.08.024
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Kessler Harald
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background & Aims: Polymorphisms of the IL28B gene (rs12979860 and rs8099917) are associated with high sustained virological response (SVR) rates in HCV genotype 1 patients. This study analyzes the impact of these IL28B polymorphisms on early treatment response (weeks 2 and 4) and SVR in HCV genotype 3 patients. Methods: rs12979860 and rs8099917 were analyzed by the Step-OnePlus Real-time PCR system in 71 out of 72 Caucasian HCV genotype 3 patients participating, at our center, in a randomized study comparing 400 mg with 800 mg ribavirin/day. HCV RNA was determined at weeks 2 and 4 of 180 mu g/week peginterferon alfa-2a/ribavirin treatment. Sixty-nine patients completed the treatment and follow-up. Results: rs12979860 genotyping revealed that 27 (37.5%) patients had C/C, 39 (54.2%) T/C, and 5 (6.9%) T/T. Thirteen patients (18.1%) became HCV RNA negative at week 2 and an additional 30 (41.7%) at week 4 (rapid virologic response; RVR); thus a total of 43 had a RVR (C/C: 77.8%; T/C or T/T: 50.0%). Irrespective of the ribavirin dose, the viral load decline was larger than in those with the T allele (T/C or T/T) (week 2: 4.46; [0.36-6.02] median; [range] vs. 3.50; [0.14-5.62]; log IU HCV-RNA/ml; p<0.001; week 4: 4.97; [1.21-6.20] vs. 4.49; [1.16-6.23]; p = 0.003). Despite the faster initial viral response in C/C carriers, SVR rates were not different compared to T-allele carriers. Results of the SNP in the rs8099917 region were similar. Conclusions: IL28B polymorphisms modulate early virologic response to peginterferon/ribavirin treatment. In contrast to HCV genotype 1 patients, no effect on SVR rates was observed in genotype 3 patients. The clinical relevance of an earlier viral decline in C/C patients needs to be determined. (C) 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Antiviral Agents - therapeutic use
- Drug Resistance, Viral - genetics
- Drug Therapy, Combination -
- Female -
- Follow-Up Studies -
- Genotype -
- Hepacivirus - drug effects
- Hepatitis C, Chronic - drug therapy
- Humans -
- Interferon-alpha - therapeutic use
- Interleukins - genetics
- Male -
- Middle Aged -
- Polyethylene Glycols - therapeutic use
- Polymorphism, Genetic - immunology
- Prospective Studies -
- Recombinant Proteins -
- Ribavirin - therapeutic use
- Treatment Outcome -
- Viral Load - immunology